

Richard N Fedorak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5004982/publications.pdf>

Version: 2024-02-01

56
papers

3,844
citations

218592

26
h-index

197736

49
g-index

56
all docs

56
docs citations

56
times ranked

4817
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1909-1916.	0.9	34
2	An overview of clinical decision support systems: benefits, risks, and strategies for success. <i>Npj Digital Medicine</i> , 2020, 3, 17.	5.7	992
3	Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization. <i>Crohn's & Colitis</i> 360, 2020, 2, .	0.5	8
4	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 170.	1.2	6
5	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
6	IBDoc Canadian User Performance Evaluation. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1107-1114.	0.9	8
7	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1515-1524.e4.	2.4	14
8	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	2.4	41
9	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	2.4	44
10	Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2018, 9, 2211.	2.2	22
11	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 115-123.	0.1	34
12	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017, 7, e016146.	0.8	35
13	Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With <i>Clostridium difficile</i> Infection. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw275.	0.4	62
14	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , 2017, 23, 3890.	1.4	28
15	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-11.	0.8	6
16	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-9.	0.8	20
17	Ulcerative Colitis Patients With <i>Clostridium difficile</i> are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 691-704.	0.2	56
18	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1895-1902.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Urine-based metabolomic analysis of patients with Clostridium difficile infection: a pilot study. <i>Metabolomics</i> , 2016, 12, 1.	1.4	6
20	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 870-879.	0.9	63
21	Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, e1-e2.	0.6	4
22	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. <i>Digestive Diseases</i> , 2016, 34, 112-121.	0.8	7
23	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 928-935.e2.	2.4	181
24	Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. <i>World Journal of Gastroenterology</i> , 2014, 20, 4934.	1.4	95
25	Development and Validation of a Highly Sensitive Urine-Based Test to Identify Patients with Colonic Adenomatous Polyps. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e54.	1.3	36
26	Real-life Treatment Paradigms Show Infliximab Is Cost-effective for Management of Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1871-1878.e8.	2.4	11
27	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1454-1463.	0.6	43
28	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	9.4	165
29	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 571-581.	0.6	66
30	Distance management of inflammatory bowel disease: Systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 829.	1.4	64
31	Canadian Digestive Health Foundation Public Impact Series 3: Irritable Bowel Syndrome in Canada. Incidence, Prevalence, and Direct and Indirect Economic Impact. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 252-256.	1.8	14
32	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	6.1	750
33	A Randomized Trial of Topical Anesthesia Comparing Lidocaine Versus Lidocaine Plus Xylometazoline for Unsedated Transnasal Upper Gastrointestinal Endoscopy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 317-321.	1.8	16
34	Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 651-655.	1.8	21
35	Canadian Digestive Health Foundation Public Impact Series: Gastroesophageal Reflux Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 431-434.	1.8	31
36	Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome. <i>Microbial Ecology in Health and Disease</i> , 2009, 21, 33-37.	3.8	6

#	ARTICLE	IF	CITATIONS
37	VSL#3 Probiotic Upregulates Intestinal Mucosal Alkaline Sphingomyelinase and Reduces Inflammation. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 237-242.	1.8	69
38	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Advanced Drug Delivery Reviews, 2005, 57, 303-316.	6.6	82
39	Probiotics and the Management of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 286-299.	0.9	155
40	Is it time to re-classify Crohn's disease?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 99-106.	1.0	11
41	Probiotics and prebiotics in gastrointestinal disorders. Current Opinion in Gastroenterology, 2004, 20, 146-155.	1.0	108
42	Trace Element Contamination of Total Parenteral Nutrition. 1. Contribution of Component Solutions. Journal of Parenteral and Enteral Nutrition, 1999, 23, 222-227.	1.3	81
43	Antigenic Mimicry Between Helicobacter pylori and Gastric Mucosa: Failure to Implicate Heat Shock Protein Hsp60 Using Immunoelectron Microscopy. Helicobacter, 1999, 4, 148-153.	1.6	10
44	Stanniocalcin: a novel protein regulating calcium and phosphate transport across mammalian intestine. American Journal of Physiology - Renal Physiology, 1998, 274, G96-G102.	1.6	74
45	Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. , 1997, 18, 681-695.		8
46	Osteoporosis of Crohn's Disease: A Critical Review. Canadian Journal of Gastroenterology & Hepatology, 1996, 10, 317-321.	1.8	0
47	Clinical Aspects of Trace Elements: Zinc in Human Nutrition - Assessment of Zinc Status. Canadian Journal of Gastroenterology & Hepatology, 1996, 10, 37-42.	1.8	11
48	Increased permeability occurs in rat ileum following induction of pancolitis. Digestive Diseases and Sciences, 1996, 41, 405-411.	1.1	13
49	Clinical Aspects of Trace Elements: Zinc in Human Nutrition - Zinc Requirements. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 368-372.	1.8	0
50	A Profile of Patients on ASA or NSAIDs Hospitalized with Gastrointestinal Perforations. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 387-392.	1.8	1
51	Vanadate reduces sodium-dependent glucose transport and increases glycolytic activity in LLC-PK1 epithelia. Journal of Cellular Physiology, 1994, 158, 459-466.	2.0	4
52	Acetic acid-induced colitis results in bystander ileal injury. Agents and Actions, 1993, 38, 76-84.	0.7	10
53	Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats. Digestive Diseases and Sciences, 1992, 37, 205-214.	1.1	79
54	Glutamine and Its Effects on the Intestine. Canadian Journal of Gastroenterology & Hepatology, 1991, 5, 94-102.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Short Bowel Syndrome. , 0, , 1295-1321.		0
56	Short Bowel Syndrome. , 0, , 340-357.		1